Results 31 to 40 of about 1,165,655 (405)

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

Dysregulation of type I interferon responses in COVID-19

Nature reviews. Immunology, 2020
Infection with SARS-CoV-2 can lead to excessive production of pro-inflammatory cytokines, but the production of type I interferons, which are key antiviral mediators, is reportedly blunted.
D. Acharya, Guanqun Liu, Michaela U. Gack   +2 more
semanticscholar   +1 more source

Interferon therapy of acute respiratory viral infections in children

Zdorovʹe Rebenka, 2017
The purpose of our study was to evaluate the efficacy and tolerability of nasal spray Laferobionum® (100,000 IU/ml) in children with acute respiratory viral infections. Materials and methods. The study included 84 children aged 12 to 18 years. Children
A.E. Abaturov, E.A. Agafonova
doaj   +1 more source

Alpha/beta and gamma interferons are induced by infection with noncytopathic bovine viral diarrhea virus in vivo [PDF]

, 2002
In contrast to the results of previous in vitro studies, experimental infection of calves with noncytopathic bovine viral diarrhea virus (ncpBVDV) was found to induce strong alpha/beta and gamma interferon responses in gnotobiotic animals.
Brackenbury, L.S, Carr, B V, Charleston, B, Fray, M D, Hope, Jayne, Howard, CJ, Morrison, Ivan   +6 more
core   +2 more sources

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. [PDF]

, 2010
Specific differences in signaling and antiviral properties between the different Lambda-interferons, a novel group of interferons composed of IL-28A, IL-28B and IL-29, are currently unknown.
A Muehlhoefer, A Ploss, AG Bowie, AJ Muir, Artur Kaul, Burkhard Göke, C Dellgren, Christoph J. Auernhammer, CJ Auernhammer, D Ge, D Henson, DL Thomas, F Terenzi, Florian Beigel, GA Deblandre, GM Almeida, H Berghall, H Kato, H Zhu, Helmut M. Diepolder, J Dambacher, JM Kelly, JM Vrolijk, JS Orange, Julia Diegelmann, K Zitzmann, Kathrin Zitzmann, KJ Blight, L Zhou, LA Zenewicz, MD Robek, MJ Clemens, N Ank, N Wang, NE Pagliaccetti, O Haller, P Osterlund, P Sheppard, PD Thomas, PI Osterlund, R Abele, R Sumpter Jr, Ralf Bartenschlager, Reuben S. Harris, RP Donnelly, S Brand, S Brand, S Brand, S Mihm, SE Doyle, SG Maher, SJ Neil, SN Sarkar, Stephan Brand, SV Kotenko, T Marcello, V Lohmann, V Lohmann, V Suppiah, W Hou, WD Rawlinson, WE Thasler, Y Benjamini, Y Tanaka, Z Liu   +64 more
core   +12 more sources

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

New England Journal of Medicine, 1998
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b
J. Mchutchison, S. Gordon, E. Schiff, M. Shiffman, William M. Lee, V. Rustgi, Z. Goodman, M. Ling, S. Cort, J. Albrecht   +9 more
semanticscholar   +1 more source

Interferon-stimulated genes: a complex web of host defenses.

Annual Review of Immunology, 2014
Interferon-stimulated gene (ISG) products take on a number of diverse roles. Collectively, they are highly effective at resisting and controlling pathogens.
W. Schneider, Meike Chevillotte, C. Rice
semanticscholar   +1 more source

Interferon-α2b Treatment for COVID-19

Frontiers in Immunology, 2020
The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In
Qiong Zhou, V. Chen, C. Shannon, Xiao-Shan Wei, Xuan Xiang, Xu Wang, Zi-Hao Wang, S. Tebbutt, T. Kollmann, E. Fish   +9 more
semanticscholar   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe, Dickson, Adele, Flowers, Paul, Hayes, Peter, Krzeczkowska, Anna   +4 more
core   +3 more sources

The type I interferon response in COVID-19: implications for treatment

Nature reviews. Immunology, 2020
Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection.
Jeong Seok Lee, E. Shin
semanticscholar   +1 more source